Veronika Bachanova, MD, PhD, discussed how the favorable safety profile of CAR natural killer cell therapies may come with trade-offs in persistence and response durability.
Veronika Bachanova, MD, PhD
Advertisement
Articles by Veronika Bachanova, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Tucatinib Combo as Maintenance in HER2+ Breast Cancer
2
Personalized Vaccines May Have Utility Across All Lung Cancer Stages
3
Selinexor-Based Quadruplet Targets Myeloma After T-Cell Redirecting Therapy
4
Firmonertinib Misses PFS End Point in First-Line EGFR Exon 20 NSCLC
5